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Background and Purpose 
Osteoradionecrosis (ORN) of the mandible is a serious complication of 
radiation therapy, and it is preceded by soft tissue damage before bone 
loss appears. ORN is defined as a condition in which irradiated bone 
becomes exposed through a wound in the overlying skin or mucosa 
and persists without healing for 3 to 6 months. In the early stage of 
ORN, soft tissue necrosis occurs and is followed by exposure of bone 
tissue. As ORN proceeds, not only the exposed cortical bone but also 
the underlying medullary bone undergoes necrosis, and eventually 
necrosis progresses to the lower body of the mandible. Because 
pathology of ORN was not understood clearly, a direct treatment 
modality has not been established for ORN. Since ORN begins from 
necrosis of soft tissue, delaying the speed of necrosis or improving 
the healing potential at this stage would minimize subsequent 
exposure of bone. After bone exposure, improvement of bony healing 
potential at the bony necrosis stage would also be beneficial in 
accelerating treatment of ORN. Recently, various effects of 
mesenchymal stem cells on wound healing have been reported. 
However, studies are lacking in the effect of application of 
mesenchymal stem cells or their combination with growth factors on 
healing of ORN at each stage.  
This study investigated the effect of platelet derived growth factor 
(PDGF) or mesenchymal stem cells (rMSCs) on radiation-induced 
soft tissue injury and the effect of rat mesenchymal stem cells (rMSCs) 
or bone morphogenetic protein-2 (BMP-2) on the osseous healing of 
osteoradionecrosis in the rat mandible, depending on application time. 
Part I. Effect on radiation induced soft tissue injury 
[Materials and Methods] Sprague-Dawley rats (n=17) were 
irradiated on the right and left buttocks with a single dose of 50 Gy. 
The right buttocks were administered with phosphate-buffered 
solution as a control. The left buttocks were administered with either 
rMSCs (2 x 106 cells), PDGF (8 µg), or PDGF combined with rMSCs. 
Administration was done at three weeks after irradiation. Wound 
healing was analyzed by calculating the percentage of residual 
ulcerated skin area compared to the total irradiated area during the 
five week healing period after administration. Modified skin scores 
were also assessed. Finally, skin lesions were histologically evaluated. 
[Results] 
More than 40% of the irradiated skin area within the irradiated zone 
underwent ulceration within 16 days postirradiation, with peak 
ulceration exceeding 50% around three weeks post-irradiation. 
Administration of rMSCs or PDGF alone did not confer any significant 
healing effect. The combined rMSCs+PDGF treatment significantly 
reduced the wound size compared with the nontreated control up to 
two weeks postinjection. Regarding the histological examination, 
lesions administered with PDGF (either alone or mixed with rMSCs) 
resulted in a greater deposition of highly organized collagen fibers 
throughout the dermis layer, compared with the control. 
 
Part II. Effect on radiation induced bony necrosis 
[Materials and Methods] The mandibles of SD rats were irradiated 
while sparing the body and internal organs by utilizing a non-occlusive 
skin clamp along with an x-ray image guided stereotactic irradiator. 
All wounds were created using the 30 Gy dose level on the right 
mandible at a 100 cm source-to-surface distance. One week after 
irradiation, all molar teeth on the right side of the mandible were 
extracted. Rats were randomly divided into two groups according to 
time of application of a hydrogel complex (n=25, each group). In 
Group 1, rMSCs and/or BMP-2 carried with hydrogel was applied 
immediate after surgery. In Group 2, it was done after the occurrence 
of ORN, four weeks after surgery. Micro-CT data of bone healing 
were compared among groups without hydrogel (n=5) and with 
hydrogel alone (n=5), or mixed with 2 x 104 of rMSCs (n = 5), or 10 
㎍ of BMP-2 (n = 5), or both of them (n = 5). Animals without 
irradiation were used as the negative control. 
[Results] 
In Group 1, BMP-2 was effective in increasing both bone volume (BV) 
and bone mineral density (BMD), while rMSCs were not. All animals 
showed ORN at irradiated areas in Group 2. In Group 2, the combined 
application of rMSCs and BMP-2 significantly increased BMD and BV 
compared to the groups without hydrogel and with hydrogel alone. 
BMP-2 application in Group 1 resulted in significantly higher BMD 
(6.29 ± 1.63%) compared to BMP-2 application in Group 2 (5.71 ± 
0.94%). 
Conclusions 
The combined administration of rMSCs and PDGF efficiently enhanced 
the healing of radiation-induced skin ulceration. Osseous healing after 
post-irradiation trauma in rats was enhanced immediately after 
dentoalveolar trauma by application of BMP-2, while the combined 
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INTRODUCTION AND REVIEW OF LITERATURE 
Radiation therapy plays a major role in the treatment of oral and 
maxillofacial malignancies, either alone or in combination with surgery 
and/or chemotherapy. However, high doses of radiation can lead to 
unwanted side effects on the skeletal system, salivary glands, and 
overlying soft tissue of the maxillofacial area. Osteoradionecrosis 
(ORN) is one of the most frequent severe complications after radiation 
therapy, and is diagnosed when irradiated bone does not heal for more 
than three months (1). The incidence of ORN is reported as 3.5%-
4.74%, and it can present clinically with various symptoms. The main 
clinical manifestation in the oral and maxillofacial area is an exposed 
necrotic bone with wound dehiscence or a fistula, though severe cases 
may include pathological fractures (2) (3).   
The pathogenesis of ORN is not clearly understood. In 1983, Marx 
described ORN as a non-healing wound resulting from metabolic and 
tissue homeostatic disturbances (1). He pointed out that ORN is a 
non-healing state after irradiation trauma, and that infection is limited 
to the contaminated surface. In contrast, Store et al. demonstrated 
through DNA-DNA hybridization that the contaminated exposed bone 
surface is generally infected by bacteria, especially anaerobes, which 
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may play a fundamental role in the pathophysiology of ORN (4). 
Recently, Delanian S et al. suggested that ORN occurs through a 
radiation-induced fibro-atrophic mechanism (5). According to this 
theory, ORN follows a sequence of free radical formation, endothelial 
dysfunction, inflammation, microvascular thrombosis (leading to 
necrosis of microvessels and local ischemia), fibrosis, and remodeling, 
which finally lead to tissue necrosis. Thus, ORN can be seen as a 
decrease in healing activity at an irradiated site that progresses 
through impaired fibroblastic activity (6). To reach the tumor, the 
radiation waves need to penetrate the skin or mucosal layer; thus, 
radiation-induced soft tissue lesions are often unavoidable (7). The 
response of soft tissue to radiation is complex (8). The epidermis is 
damaged in the early stage of radiation, whereas later effects arise 
from insult to the dermal vasculature. One or two days after radiation 
exposure, temporary erythema appears, which is then followed by a 
more intensive erythematous reaction. Afterwards, dermal ischemia 
and dermal necrosis occur, resulting in soft tissue damage such as 
dermal atrophy and invasive fibrosis (9). In this way, response of soft 
tissue to radiation accelerates bony exposure.  
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Because the exact pathogenesis of ORN is unclear, a definitive 
treatment modality has not been established. Conventional treatment 
for radiation-induced soft tissue ulceration with superficial dressings 
requires a long healing period and frequently leaves residual lesions 
via atrophy, fibrosis, or bony exposure. This is especially true for 
long-term nonhealing ulcers that eventually require surgery (10). 
Conventional treatment is mostly based on symptomatic therapy, and 
consists of sequestrectomy, debridement, and surgical resection of 
the jaw bone, with or without defect reconstruction in severe cases, 
followed by meticulous wound closure (11).  However, despite 
meticulous postoperative care, recurrent ORN is frequent and results 
from delayed wound healing and wound dehiscence with secondary 
infection, due to the reduced healing capacity after irradiation. 
To overcome these disadvantages, a number of alternative 
treatments have been introduced (12-15). Among these alternatives, 
mesenchymal stem cells (MSCs) have shown the capacity to repair 
hard and soft tissue damage in animal models (16) and human patients 
(17, 18). With respect to their therapeutic effects on soft tissue 
damage, efficient results have been reported in animal models of lung 
injury (19), kidney injury (20), and myocardiac infarction (21). MSCs 
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produce various cytokines and adhesion molecules for hematopoiesis, 
and are known to participate in angiogenesis and wound repair (22). 
MSCs also express proangiogenic factors that regulate endothelial cell 
migration and capillary proliferation, and have been reported to be 
involved in vessel remodeling (23).  
MSCs or growth factors can contribute to tissue regeneration in 
damaged tissue with an impaired healing capacity (24, 25), as seen in 
ORN (26). Bone marrow mesenchymal stromal cells had a therapeutic 
effect on ORN in a swine model (26). In another series of studies, 
MSCs were subcutaneously transplanted into immunocompromised 
mice, which led to the formation of organ-like structures including 
newly formed bone and associated hematopoietic marrow components 
(27-29).   
Among the numerous identified growth factors, platelet-derived 
growth factor (PDGF) is considered particularly critical for vascular 
formation. The homodimer PDGF-BB responds to hypoxia, growth 
factors, and shear stress and is expressed highly at the sprouting tip 
of forming capillaries, where it contributes to pericyte recruitment 
(30). PDGF-BB also stimulates pericyte production of extracellular 
matrix proteins, including fibronectin, collagen, and proteoglycans, 
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which are necessary for the basement membrane of capillaries. In 
addition, PDGF-BB upregulates the expression of vascular endothelial 
growth factor (VEGF) in mural cells and stimulates fibroblasts to 
produce and secrete collagenases, which are key for cell migration in 
angiogenesis (31). 
Bone morphogenic protein-2 (BMP-2) is regarded as the most 
potent growth factor for bone regeneration (32-34). It may be also 
effective for tissue repair in ORN, as predictable bone generation was 
seen after the application of BMP-2 in a rat mandible ORN model (25). 
Animal ORN models have shown that inhibition of endogenous BMP-
2 and osteocalcin (35). Therefore, exogenous BMP-2 should be able 
to enhance osseous regeneration in ORN. This exogenous BMP-2 and 
MSC therapy should be applied at the optimal time, where these 
substitutes can act most effectively to repair tissue. However, it is 
unclear whether the best time of administration is immediately after 
tissue damage (e.g., tooth extraction) or after occurrence of 
pathologic status (e.g., ORN).  
Even though a synergic regeneration efficacy can be expected with 
a combination of MSCs and PDGF/BMP-2, the effect of combined 
therapy in the ORN model has not been investigated. The purpose of 
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this study was to investigate the effect of MSCs and/or PDGF alone 
for treating radiation-induced soft tissue injury and the effect of 
MSCs and BMP-2 on the osseous healing of ORN in the rat mandible 
at two different administration times. 
 
 
PART I. EFFECT ON RADIATION INDUCED SOFT TISSUE 
INJURY 
 
A. Materials and methods 
1. Animal model of radiation-induced skin ulceration  
All animals in these studies(part I and part II) were treated and 
handled in accordance with the “Recommendations for Handling of 
Laboratory Animals for Biomedical Research ”  compiled by the 
Committee on the Safety and Ethical Handling Regulations for 
Laboratory Experiments at the School of Dentistry, Seoul National 
University. 
Adult male Sprague-Dawley (SD) rats (n=18; mean mass, 120 g) 
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(Orientbio Inc. Seongnam. Korea) were irradiated on both buttocks at 
six weeks of age. For each animal, the left buttock was assigned as 
the experimental side and the right buttock was assigned as the 
control side. After intraperitoneal injection of Zoletil 50 (0.1 mg/100 
g) (Virbac, Paris, France), the buttocks of each rat were shaved and 
prepared with povidone-iodine solution (MEDICA KOREA, Seoul, 
Korea). Rats were irradiated with a single electron beam delivered by 
a Clinac iX linear accelerator (Varian Medical System, Inc., Palo Alto, 
CA, USA). The total irradiated area for each buttock was 3.5 cm x 3.5 
cm = 12.25 cm2. A 3-mm lead filter was added to the skin site to 
remove low energy photons from the beam at a 100 cm source-to-
surface distance. Radiation (50 Gy, 6 MeV electron, 5501 MU) was 
delivered to 3.5 cm x 3.5 cm areas on the skin (depth range, 2 mm) 
of both buttocks. Rats were housed individually to prevent gnawing of 
wounds and other potentially damaging interactions.  
 
2. Preparation and culture of rMSCs  
Bone marrow aspirate was obtained from rat tibias. Rat MSCs were 
cultured according to the protocol described by Caterson et al. (36). 
Briefly, the marrow suspension was collected in a syringe containing 
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6000 U/mL heparin (JW Pharmaceutical Co., Seoul, Korea), mixed 
with an equal volume of phosphate-buffered solution (PBS) (Gibco, 
Rockville, MD, USA), and spun by centrifugation at 2500 rpm for 10 
min. After aspirating the upper PBS layer, the marrow suspension was 
layered onto Ficoll-Paque (1:5 ratio) (GEHealthcare Life Sciences, 
Piscataway, NJ, USA) and spun by centrifugation at 2580 rpm for 30 
min. Nucleated cells, which concentrated at the interface, were 
collected and washed with PBS. Adherent cells were plated at a 
density of 2 x 106 cells/100 mm dish and cultured in expansion medium 
containing alpha-MEM (Welgene Inc., Gyeongsan, Korea), 100 
units/mL penicillin (Gibco, Rockville, MD, USA), 100 μg/mL 
streptomycin (Gibco, Rockville, MD, USA), and 10% heat inactivated 
FBS (HIFBS) (Gibco, Rockville, MD, USA) under a humidified 
atmosphere of 5% CO2 at 37℃. Culture medium was changed every 3 
or 4 days. rMSCs were passaged upon reaching 70% confluence. All 
experiments were performed using cells in their fifth passage.  
 
3. Flow cytometry 
rMSCs in their fifth passage were resuspended in phosphate-
buffered saline (PBS) at 1x105 cells/mL and then incubated with 
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fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies 
against CD90 (LifeSpan Biosciences Inc., Seattle, WA, USA) or CD45 
(LifeSpan Biosciences Inc.), each diluted to 1:200 in PBS. 
Alternatively, cells were incubated with anti-mouse IgG (BD 
Biosciences, San Jose, CA, USA) as an isotype control. Cells were 
incubated for 30 or 90 min in the dark after being washed with 1% 
bovine serum albumin in PBS (BSA/PBS). Cells were washed twice 
with BSA/PBS and resuspended in BSA/PBS with 0.1% 
paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) for 
fluorescence-activated cell sorting (FACS) analysis. Cells were then 
fixed in 70% alcohol and sorted using a BD FACS Aria Cell Sorting 
System (BD Biosciences, San Jose, CA, USA). 
 
4. Application of rMSCs and PDGF 
Throughout the study, identical doses of rMSCs and/or PDGF were 
used in all groups. Moreover, the cell density also remained constant 
among the groups (1x106 rMSCs/cm2), which has been shown to be 
adequate for effective tissue regeneration (12). rMSCs and PDGF 
were applied three weeks after irradiation, identical amounts of rMSCs 
(2x106 cells/2ml) and PDGF (8 μg) were evenly injected 
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subcutaneously over the entire ulcerative skin lesion, which varied in 
location and size (Figure 1(a)). For rMSC delivery, 1 mL of rMSC 
suspension (1x106 cells/ml in PBS) was filled in 1 ml syringe and total 
2 syringes of rMSCs were injected subcutaneously at each site. As a 
control, 1 mL PBS was injected into each site on the control side. 
Animal study only included animals for which the radiation-induced 
ulcers on the experimental side and control side did not exhibit any 
significant differences in size at three weeks after irradiation. One rat 
was excluded because its ulceration ratios were significantly different 
between the control and experimental sides (24.04 % vs 50.24 %). 
Animals (n=17) was subdivided into three groups: Group A: rMSCs 
(n=6), Group B: PDGF (n=6), and Group C: rMSCs+PDGF (n=5). 
Skin ulcers were measured over a five-week healing period after the 
administration of rMSCs and/or PDGF. Five weeks after treatment, 
skin samples were evaluated histologically by hematoxylin and eosin 
(H&E) staining and Masson’s trichrome (MT) staining. To verify the 
presence of the delivered rMSCs, two rats were injected with 
fluorescent dye-labeled rMSCs at three weeks post-irradiation. The 
rats were sacrificed on the 3rd and 7th days postinjection, respectively, 
and the presence of the delivered rMSCs was verified. These two rats 
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were excluded from statistical analysis. 
 
5. Wound model and wound healing assay 
Acute skin reactions were assessed by visual scoring 21 days after 
irradiation. Assessment continued every three days until 35 days 
postinjection. Skin reactions were scored at each time point; data are 
presented as means. For scoring, the modified skin score system was 
used as follows: 0, normal; 0.5, slight epilation; 1.0, epilation in 
approximately 50% of the irradiated area; 1.5, epilation in more than 
50% of the area; 2.0, complete epilation; 2.5, dry desquamation in 
more than 50% of the area, 3.0, moist desquamation in a small area; 
and 3.5, moist desquamation in most of the area (37).   
For wound size analysis, the irradiated area of each rat was 
photographed with a digital camera at each time point. From these 
images, the percentage of the ulcerated area was determined by 
calculating the ratio of the ulcerated area to the total irradiated area 
using ImageJ, version 1.47 (NIH, Bethesda, MD, USA) (Figure 1(b)). 
The total irradiated area and ulcerated area were marked three times 
while blinded to the group assignments, and the average values of 
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these measurements were used for assessment. The irradiated area 
was defined as the area in which hair loss was observe (37). The 
ulcerated area was defined by scabbing, crusting, or desquamation. 
The numbers of pixels within each zone were calculated using ImageJ, 
and these values were used to calculate the percentage of skin 
ulceration within the irradiated zone. 
 
6. Histological examination 
Samples were fixed in 10 % formalin-buffered solution (Duksan 
Pure Chemicals Co. Ansan-si. Korea) and embedded in paraffin wax 
(Leica Biosystems Nussloch GmbH, Nußloch, Germany). For 
histochemical staining, the paraffin sections were cleaned with xylene 
(Duksan Pure Chemicals Co. Ansan-si. Korea) for ten minutes. Next, 
four-μm-thick slices were prepared and stained with both 
Hematoxyline and Eosin (H&E) (Sigma-Aldrich, St. Louis, MO, USA) 
and Masson’s trichrome (MT) (Sigma-Aldrich, St. Louis, MO, USA). 
Digital images of the stained sections were captured for histological 
evaluation using a transmission and polarized light Olympus BX51 
Axioskop microscope (Olympus Corp., Tokyo, Japan). Skin damage in 
the affected areas (epidermal atrophy, number of lymphocytes, dermal 
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degeneration such as edema and collagen fiber loss) is expressed as 
percentages. Skin damage was scored on a 5-point ordinal scale as 
previously described (14, 38): Grade 0 = normal, Grade 1 = minimal, 
Grade 2 = mild, Grade 3 = moderate, Grade 4 = marked, and Grade 5 
= severe. 
 
7. Labeling of rMSCs with dialkylcarbocyanine  
rMSCs were labeled with the fluorescent dye dialkylcarbocyanine 
(Dil; Molecular Probes®, Thermo Fisher Scientific Inc., Waltham, MA, 
USA) by incubating cells in medium containing Dil (final concentration 
10 ng/mL) for 24 hours. Dil-labeled rMSCs were injected 
subcutaneously into the left side of the irradiated buttocks of two rats. 
Histological specimens were prepared after sacrifice at three and 
seven days postinjection as described above, and the presence of 
rMSCs was verified using a confocal laser scanning microscope (Carl 
Zeiss Micro Imaging GmbH, Jena, Germany). To investigate the 
viability of rMSCs, the expression of proliferating cell nuclear antigen 





8. Statistical analysis 
All wound healing data are reported as means ± standard 
deviations. Data were checked for a normal distribution using the 
Kolmogorov–Smirnov test. When data were normally distributed, the 
experimental side was compared with the corresponding control side 
using a paired t-test. Data with non-normal distributions were 
compared using the Wilcoxon signed-rank test. All statistical 
analyses were performed with SPSS (ver. 18.0, SPSS, Chicago, IL, 
USA). Differences between values were considered statistically 




As shown in Fig. 2, CD45 and CD90 could be detected by flow 
cytometric analysis. No systemic or lethal sequelae occurred in any 
animal. Moreover, no recognizable changes were observed on the 
irradiated skin until one week postirradiation. The first observable 
change was hair loss at 7 days postirradiation; ulcerative skin changes 
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were first seen at 10 days postirradiation. By day 14, necrotic changes 
were observed throughout the entire skin layer of the irradiated area. 
Peak ulcer size was observed on the 21st day postirradiation. 
Ulcerative lesions occurred independently of the injection site after 
irradiation and varied in location, size, and shape. 
The modified skin scores were ranged from 3 to 3.5 at the time of 
injection on both the experimental and control sides of each animal; 
these scores decreased to 2 - 2.5 according to the follow-up period 
(Figure 3, Table 1). In Groups A and B, the scores decreased to 3.0 
after 7-8 days, with no significant difference between the 
experimental and control sides. In Group C, the scores decreased to 
3.0 after only 2 days; however, no significant difference was observed 
between the experimental and control sides (Figure 3). 
1. Ulceration size evaluation 
rMSCs alone or PDGF alone did not markedly enhance macroscopic 
healing of the radiation-induced skin wound, while rMSCs+PDGF 
treatment significantly aided the early stage of wound healing. In 
Group A, the ulceration ratios at the time of injection were 38.51 ± 
10.74% on the experimental side and 41.60 ± 7.78% on the control 
side. Ulcer size decreased significantly during the first two weeks 
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postinjection on both sides, whereas the reduction rate decreased 
after this time. However, the ulceration ratio on the experimental side 
was not significantly different compared with the ratio on the control 
side. If anything, the ratio tended to be smaller on the control side. At 
five weeks postinjection, the average ulcerative lesion size on the 
experimental side was 1.37 ± 0.73%, and two out of the six rats 
showed no ulcerative skin lesions at all. The ulceration ratio on the 
control side was 0.82 ± 0.97%; all six rats exhibited ulcerative 
lesions on the control side (Figure 4(a), Table 2).  
In Group B, the ulceration ratios at the time of injection were not 
significantly different (50.22 ± 5.10% on the experimental side vs. 
45.11 ± 6.78% on the control side). The ulceration ratios decreased 
over time. As in Group A, ulcer size decreased most dramatically 
during the first two weeks after the injection, after which the reduction 
rate decreased. However, no significant difference was observed 
between the both experimental and control sides at five weeks 
postinjection. At this time, four out of the six rats showed ulceration 
on the experimental side, while two out of the six rats showed 
ulceration on the control side (Figure 4(b), Table 2).  
In Group C, the ulceration ratios were also not significantly different 
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at the time of injection (44.40 ± 7.54% on the experimental side vs. 
46.39 ± 12.54% on the control side, Figure 4(c), Table 2). However, 
the two sides did exhibit significant differences in healing after 
treatment. Three days after treatment, the ratios were 31.56 ± 
14.03% and 35.79 ± 13.11% on the experimental and control sides, 
respectively (p=0.015). At seven days postinjection, the difference 
between the two sides had decreased (25.00 ± 10.49% vs 26.57 ± 
10.54% on the experimental and control sides, respectively; p=0.045). 
At ten days, the ulceration ratio was still significantly smaller on the 
experimental side (18.58 ± 11.45%) than the control side (20.60 ± 
10.30%) (p=0.004). Two weeks after the injection, however, no 
significant difference was observed (18.20 ± 13.46% vs. 17.21 ± 
10.94%) (Figure 5). At five weeks postinjection, two of the five rats 
exhibited ulceration on the experimental side, while five of the six rats 
showed ulceration on the control side. 
 
2. Histological examination 
Histological examination of the skin ulcers was performed at five 
weeks postinjection. All three treatments (rMSCs alone, PDGF alone, 
and rMSCs+PDGF) resulted in positive microscopic effects on wound 
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healing.  In Group A, erosion of the epidermis layer was observed in 
43.99 ± 15.20% of the control skin area, and edema (Grade 3-4) 
was present in all specimens. In contrast, the experimental side of 
Group A tended to show less erosion of the epidermis layer (25.00 ± 
16.42%). Moreover, edema was observed in half of the experimental 
specimens (3/6) and the edema intensity was less (Grade 2) 
compared with the control side (Figure 6(a), 6(b)). In Group B, the 
epidermis layer showed erosion in 33.33 ± 22.51% of the control 
area, and edema (Grade 3) was present in five out of the six rats. In 
contrast, the experimental side showed less erosion of the epidermis 
layer (15.00 ± 17.61%), and edema (Grade 2-3) was present in four 
out of the six rats. In Group C, the control side showed erosion in 
48.61 ± 21.05% of the epidermis layer, and edema (Grade 3-4) was 
present in all six animals. The experimental side tended to show less 
erosion of the epidermis layer (37.18 ± 23.83%), and edema (Grade 
2-3) was present in four out of the six animals. These differences in 
epidermal erosion and presence of edema were not significant. The 
wounds were re-epithelialized with regenerated skin appendages in 
Group C, while the control group exhibited less re-epithelialization 
and regeneration of skin appendages (Figure 6(e), 6(f)).  
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MT staining revealed more organized collagen fiber deposition 
throughout the full thickness of the dermis layer when PDGF was 
administered (either alone or in combination with rMSCs) compared 
with the vehicle control (Figure 6(c), 6(d)).  
To track the transplanted rMSCs, Dil-labeled rMSCs were traced at 
three and seven days postinjection. Dil-labeled rMSCs were observed 
at each time point and were located mainly between the epithelial layer 
and the dermis layer. Expression of PCNA was verified (Figure 7).  
 
 
PART II. EFFECT ON RADIATION INDUCED BONY NECROSIS 
 
A. Materials and methods 
1. Materials 
Hyaluronic acid (HA: MW 170,000 Da) was purchased from 
Lifecore Biomedical (Chaska, MN, USA) and 1-




carbodimide, triethanolamine and adipic acid dihydrazide (ADH) were 
acquired from Sigma-Aldrich (St. Louis, MO, USA). N-
acryloxysuccinimide was purchased from Acros Organics (Pittsburgh, 
PA, USA), and RGD peptides and MMP-insensitive peptides were 
obtained from AnyGen. (Gwang-ju, Korea). Escherichia coli-derived 
rhBMP-2 powder was provided from Daewoong Co. (Seoul, Korea), 
and dissolved with stabilizing buffer which was obtained by 
manufacture, at a concentration of 1 mg/mL. NFAT inhibitor 
(SigmaeAldrich, St. Louis, MO, USA) was prepared by dissolving 50% 
acetic acid at a concentration of 5 mM. Ficoll-paque plus was obtained 
from Amersham Biosciences (Uppsala, Sweden). Fetal bovine serum 
(FBS), penicillin/streptomycin, trypsin, and low-glucose Dulbecco’s 
Modified Eagle’s Medium (DMEM) were purchased from GIBCO BRL 
(Grand Island, NY, USA). 
 
2. Preparation of hydrogel and synthesis of a MMP sensitive 
hyaluronic acid based hydrogel  
Synthesis of MMP sensitive HA-based hydrogel was performed as 
described previously (39, 40). For gel preparation, MMP-sensitive 
peptides (GCRDGPQGIWGQDRCG) or MMP-insensitive peptides 
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(GCRDGDQGIAGFDRCG) were added to acrylated HA solution with 
the same molar ratio of acryl and thiol groups (41, 42). The HA-based 
hydrogel was formed using a Michael-type addition reaction (43). Cell 
adhesion peptides (RGDSP) were also immobilized on the acrylated 
HAs with a molar ratio of 20% of acryl groups of the HA. The reaction 
mixture was incubated at 37℃ for gelation. For each rat, 12 ㎕ of 
hydrogel (0.464 mg / 8 ㎕ of 4 wt % hydrogel with 230 kDa HA + 
0.128 mg / 2 ㎕ of MMP sensitive peptides (80%) + 0.048 mg / 2㎕ 
RGD (20%)) were used. The mechanical properties and specific 
degradability of MMP sensitive HA-based hydrogels were described 
previously (39). 
 
3. Preparation and culture of rat mesenchymal stem cells (rMSCs) 
Bone marrow aspirate was obtained from rat tibias. MSCs were 
cultured as described previously in part I (36).  
The hydrogels with or without 2 ㎕ of BMP-2 (10 ㎍/construct) 
were mixed with 2 ㎕ of PBS with passage 5 MSC suspensions (2 x 
104 cells/construct) to produce a final volume of 16 ㎕ for each group. 
The samples were cross-linked for one hour at 37 ℃. The cells in 
the hydrogels were cultured in DMEM with 10% (v/v) FBS and 1% 
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(v/v) antibiotics, containing penicillin and streptomycin in a humidified 
incubator (5% CO2, 37℃) overnight. MSC viability was verified in a 
previous experiment (41). The amount of rMSCs was determined by 
mixing a hydrogel construct with four different cell numbers (1 x 106 
cells/construct, 1 x 105 cells/construct, 1 x 104 cells/construct, 2 x 
104 cells/construct); the maximum cell number of rMSCs allowing for 
gelation was 2 x 104 cells/construct, and this amount was used for the 
experiment.  
 
4. Animals and irradiation  
One hundred fourteen Sprague-Dawley (SD) rats (seven-week-
old male) (Orientbio Inc. Seongnam, Korea; average mass of 205 
grams) were used. 49 rats died during the development of the ORN 
model (supplementary results), and 65 rats were included in this 
study. Six rats underwent only the surgery without irradiation as the 
negative control group. The negative control group was used in the 
development of the ORN model and to analyze the effects of hydrogel 
containing rMSCs or BMP-2. 59 rats received surgery after 
irradiation. Of these, nine rats were used for pilot experiments, in 
which three rats were utilized to confirm the occurrence of ORN four 
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weeks after surgery (Figure 8) and six rats were sacrificed to 
determine the appropriate dose of BMP-2. Hydrogels containing 5 ㎍, 
10 ㎍, and 20 ㎍ of BMP-2 were administered to two rats for each 
dose, and the new bone formation was assessed after four weeks. The 
bone volume in the region of interest was 0.32 ㎣ in rats treated with 
5 ㎍ BMP-2, 1.03 ㎣ in rats treated with 10 ㎍ BMP-2, and 0.37 ㎣ 
in rats treated with 20 ㎍ BMP-2. Therefore, we used 10㎍ of BMP-
2 in this study. Finally, 50 rats which received irradiation were 
included to evaluate efficacy.  
Before extraction, animals were irradiated using an X-ray (Clinac 
iX, Varian Medical System, Inc., Palo Alto, CA, USA). Under general 
anesthesia with Zoletil 50 (0.1mg/100g) (Virbac, Paris, France), the 
right mandible was shaved and disinfected with povidone-iodine 
solution (MEDICA KOREA, Seoul, Korea), and a single dose of 30 Gy 
(6 MeV electron, 600MU/min) was administered to the right 
mandibular body. Rats were housed individually to prevent gnawing of 
wounds and other potentially damaging interactions. One week after 
irradiation, three right mandibular molars were extracted and a bony 
defect was created under general anesthesia using intraperitoneal 
injection of ketamine hydrochloride (Ketara®, Yuhan Corp. Korea, 40 
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mg/kg) mixed with xylazine (Rumpen® Bayer Korea Ltd., Korea, 10 
mg/kg). After molar extractions, a bone defect sized 4 ㎜ in length, 2 
㎜ in width, and 1.5 ㎜ in height was created with a surgical curette 
and a dental rotary handpiece.  
The animals that underwent surgery after irradiation (n = 50) were 
divided into two groups (Table 3). In Group 1, the hydrogel construct 
was applied immediately after the extraction and creation of the bony 
defect (Groups 1b, 1c, 1d, 1e, n = 20), while the hydrogel construct 
was not inserted in the positive control (Group 1a, n = 5). In Group 2, 
the hydrogel construct was applied four weeks after surgery when 
ORN had already occurred (Groups 2b, 2c, 2d, 2e, n = 20), while the 
hydrogel construct was not inserted in the positive control (Group 2a, 
n = 5). In Group 1, the hydrogel construct was applied after verifying 
hemostasis, and wound closure was performed with 6-0 nylon. The 
maintenance of wound closure with the suture material was checked 
one, three, and seven days after surgery. In Group 2, we confirmed 
wound dehiscence in the exposed alveolar bone four weeks after 
surgery, and then the contaminated necrotic bone was removed by 
surgical curettage after wound disinfection. Thereafter, the hydrogel 
construct was applied and the primary wound closure was performed 
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with 6-0 nylon. As in Group 1, the maintenance of wound closure with 
the suture material was checked one, three, and seven days after 
surgery (Figure 8). 
The sub-classifications of Group 1 and 2 are as follows, depending 
on the contents of hydrogel construct: Group 1a/2a (n=5 for each), no 
hydrogel in the bone defect; Group 1b/2b (n=5 for each), hydrogel 
(16 ㎕) only; Group 1c/2c (n=5 for each), hydrogel (16 ㎕) 
containing rMSCs (2 x 104 cells); Group 1d/2d (n=5 for each), 
hydrogel (16 ㎕) containing BMP-2 (10 ㎍); and Group 1e, 2e (n=5 
for each), hydrogel (16 ㎕) containing rMSCs (2 x 104 cells) and 
BMP-2 (10 ㎍).  
The occurrence of ORN was investigated during the harvest of the 
mandibular bone segment, whether alveolar bone was exposed or 
covered fully with soft tissue mucosa. 
 
5. Micro-CT analysis 
Micro-computed tomography was done with SkyScan 1172® 
(SkyScan®, Kontich, Belgium). The SkyScan 1172® microfocus X-ray 
system was equipped with a microfocus X-ray tube with a focal spot 
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of 2 ㎛, producing a cone beam that was detected by a 12-bit cooled 
X-ray camera that was charge coupled device (CCD) fiber-optically 
coupled to a scintillator. The resulting images for two-dimensional 
and three-dimensional (3D) analysis were square 512 x 512 pixel 
images. An optimized 3D cone beam reconstruction algorithm with a 
cluster volumetric reconstruction (Feldkamp algorithm) was used. 
The scan parameters were 20-100 kV, 10 W with rotation. A full 
three-dimensional image containing the experimental area and the 
surrounding trabecular bone was obtained with a cubic voxel size of 
24 ㎛, resulting in about 400 two-dimensional images per specimen. 
Image analysis was done with CTAn 1.8® (SkyScan®, Kontich, 
Belgium), and 3D reconstruction was done with NRecon 1.6.9.8® 
(SkyScan®, Kontich, Belgium). Using three-dimensionally 
reconstructed images, regions demonstrating consistent bony 
necrosis and bone formation were designated as the region of interest 
(ROI). Each ROI was defined as a volume of 50 pixels in width by130 
pixels in height by 132 pixels in length. Micro-CT image analysis was 
done by assessing the volume and quality of bone. Tooth root rests 
within the ROI were excluded, and only bone tissue was assessed. 
Roots could be distinguished from bone with the naked eye in each 
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cross-section and were well separated from bone by the surrounding 
radiolucent space (periodontal ligament). The specific thresholds for 
mineralized bone were defined by superimposing original segmented 
images over grayscale images. Equivalent thresholds were applied for 
every image to divide mineralized bone from the background. Within 
the ROI, bone mineral density (BMD) (%), bone volume (BV) (㎣), 
trabecular thickness (Tb.Th) (㎜), trabecular number (Tb.N) (1/㎜), 
and trabecular separation (Tb.Sp) (㎜) were measured and compared 
(Figure 9). 
 
6. Histological evaluation 
After Micro-CT reconstruction, we resected and decalcified the 
surgical fields at the mandible using ethylene diamine tetra-acetic 
acid solution (7%, pH 7.2) for 3–4 days, with replacement of the acid 
solution on day 2. The specimens were then dehydrated in 70% 
ethanol, fixed in 10% formalin-buffered solution (Duksan Pure 
Chemicals Co. Ansan-si, Korea), and embedded in paraffin wax (Leica 
Biosystems Nussloch GmbH, Nußloch, Germany). For histological 
staining, decalcified paraffin sections were cleaned with xylene 
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(Duksan Pure Chemicals Co.) for ten minutes, and four-㎛-thick 
slices were prepared and then stained with both hematoxylin and 
eosine Y (H&E) (Sigma-Aldrich) and Masson’s trichrome (MT) 
(Sigma-Aldrich) to detect cells and regenerated bone structures. 
Digital images of the stained sections were collected for histological 
evaluation using a transmission and polarized light Axioskop 
microscope, Olympus BX51 (Olympus Corp., Tokyo, Japan). Bone 
tissue characteristics of the experimental and control groups were 
compared. Histomorphometric evaluation was not performed, because 
histological images did not represent osseous healing due to irregular 
healing patterns in the bony defects.  
 
7. Statistical analysis 
All data from computed tomographic scans were presented as mean 
± standard error of mean in each experimental group (n = 5). The 
normality of the distribution of the data was confirmed qualitatively 
using the Kolmogorov-Smirnov test. Two-way ANOVA with a 
Bonferroni correction was used to analyze the effects of application 
time and application material. One way ANOVA was used to analyze 
the effect of the application material within groups. For the groups that 
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showed an abnormal distribution, the Kruskal-Wallis test was applied 
to compare the computed tomographic data. Results were considered 
statistically significant at p < 0.05. Statistical analysis was performed 




1. Development of the ORN Model in SD rats 
The total number of animals in the beginning of the study (n = 114) 
was much greater than the number of animals included for the 
evaluation of efficacy (n = 65) when creating this rat ORN model. 
Molar roots were frequently fractured during extraction, and the 
alveolar bone exposure in extraction sockets differed depending on 
the existence and size of root rests. Therefore, a bone defect after 
molar extraction was created with a surgical curette and a dental 
rotary machine to create similar alveolar bone exposure in all animals. 
However, the creation of an alveolar bone defect in the rat mandible 
seemed too traumatic for the inferior alveolar artery, which often 
ruptured during this surgical procedure; 16 rats (14 rats in group 1, 2 
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rats in group 2) died due to excessive hemorrhage from the inferior 
alveolar artery or airway obstruction from a blood clot. Moreover, the 
pain resulting from damage to the inferior alveolar nerve during the 
surgical procedure woke animals up from the anesthesia, and the 
additional anesthetic injections led to complications (mainly overdose) 
in 15 rats (13 rats in group 1, 2 rats in group 2). 18 rats (10 rats in 
group 1, 8 rats in group 2) died during the postoperative check-up 
period with unclear etiology. Ultimately, only 65 rats were included in 
this experiment. The mortality for the development of ORN model was 
43.0% (49/114 rats). The occurrence of bone necrosis without the 
coverage of mucosal soft tissue could be observed in all animals during 
the harvest of the mandibular bone segment for histological evaluation. 
In Group 1, the postoperative follow-up period was four weeks. In 
Group 2, it was eight weeks because of the different administration 
time. Alopecia and undergrowth of the ipsilateral incisor were 
observed on the irradiated right side of the mandible. Hair loss and 
incisor undergrowth were not observed on the opposite side.  
In the negative control group in the pilot experiment, where 
extraction was done without irradiation, 3D micro-CT analysis 
showed an average bone volume of 4.78 ± 1.53 ㎣ and an average 
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BMD of 1.50 ± 0.07% in the extraction socket four weeks after 
extraction. The experimental group in the pilot experiment showed an 
average bone volume of 2.26 ± 1.94 ㎣ and an average BMD of 1.34 
± 0.10%. Both bone volume and BMD were significantly lower in the 
experimental group from the pilot experiment (p=0.016, p=0.039, 
respectively). Histologically, bone loss and ingrowth of fibrotic tissue 
in the bone marrow of the irradiated area were observed. Blood 
vessels at the irradiated area were obstructed with signs of vitreous 
degeneration (Figure 10). 
 
2. Effect of hydrogel with BMP-2 and MSCs depending on 
different application time. 
2.1. Micro-CT results 
2.1.1. Bone healing in Group 1  
The mean values for BV and BMD are presented in Table 4. Among 
the subgroups in Group 1, only the positive control (Group 1a) showed 
clearly lower BV compared to the negative control; the BV of all other 
subgroups was similar or higher. BMD in Group 1c was similar to the 
negative control, while Group 1d had a higher BMD than the negative 
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control. BMD in other subgroups was lower than that of the negative 
control. Only Group 1d had more effective bone healing than the 
positive control; when BMP-2 was applied immediately after defect 
formation, BV and BMD were significantly higher four weeks after 
surgery than BV (p = 0.001) and BMD (p = 0.002) in the positive 
control (Group 1a) (Figure 11(a)). Application of rMSCs, either alone 
or in combination with BMP-2, had no significant effect on the 
increase in BV or BMD. Our results suggest that BMP-2 is effective 
for increasing both BV and BMD, while rMSCs are not effective for 
increasing BV and BMD (Figure 12). In addition, only BMP-2 alone 
effectively increased Tb. N compared to Group 1a (p=0.027). No 
significant differences among groups were found for Tb.Th and Tb.Sp.  
 
2.1.2. Bone healing in Group 2 
The mean BV and BMD values are presented in Table 4. Groups 2a 
and 2b showed clearly lower BV than the negative control, while 
Groups 2c, 2d and 2e had higher BV than the negative control. BMD in 
Groups 2c and 2e was similar to the negative control, while BMD was 
slightly lower in Group 2d and was clearly lower in Groups 2a/2b. 
Groups 2c, 2d and 2e had more effective healing than the positive 
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control (group 2a), indicating that BMP-2 and/or rMSCs application 
led to increased BV (Figure 11(b)). Group 2e showed a significant 
increase in BMD when compared to Group 2a (p=0.01) and Group 2b 
(p=0.000). Group 2c showed significantly increased BMD compared 
to Group 2b (p=0.002). These results suggested that application of 
rMSCs could increase BMD (Figure 13). Tb.Th was significantly 
increased in Groups 2c and 2d when compared to group 2b (p=0.006, 
p=0.008), and Tb.N was significantly increased in Group 2e when 
compared to group 2b (p=0.013). Tb.Sp showed no significant 
differences among groups.  
 
2.2. Histological results 
2.2.1. Development of ORN 
Four weeks after extraction and bony defect formation in irradiated 
bone, specimens showed fibrosis, infiltration of inflammatory cells into 
inter-trabecular spaces, necrotic bony change of the trabecular bone, 
and empty lacunae (Figure 10).  
 




Epithelial tissue at the defect area was incompletely regenerated in 
Groups 1a and 1b, while Groups 1c, 1d, and 1e showed complete 
regeneration. In Groups 1c, 1d and 1e, normal bone/marrow structure 
could be observed, but there was slight inflammation in Groups 1a and 
1b (Table 5) (Figure 14(a), 15(a), 15(b)). 
In Group 2, epithelial tissue at the ORN area was poorly regenerated 
in Groups 1a and 2b, while Groups 2c, 2d, and 2e showed epithelial 
coverage of alveolar bone. In groups 2a and 2b, there was almost no 
new bone formation and no epithelial lining over the alveolar bone. In 
addition, we observed resorptive changes including inflammation and 
numerous empty lacunae. In contrast, when rMSCs were applied, there 
was almost no infiltration of inflammatory cells, and alveolar bone was 
regenerated with normal bone structure, but with small bone defects 
at the alveolar crest (Table 5) (Figure 14(b), 15(c), 15(d)). 
 
2.1.3. Comparison between Group 1 and 2 
BV was significantly smaller when hydrogel alone was applied after 
the occurrence of ORN (Group 2b) (1.32 ± 0.78 ㎣) when compared 
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to the rats who received an immediate application of hydrogel (Group 
1b: 4.27 ± 0.45 ㎣) (p=0.034). Tb.N varied based on the time of 
BMP-2 application. BMP-2 application immediately after extraction 
resulted in significantly higher Tb.N (1.33 ± 0.44 /mm) compared to 
BMP-2 application after the occurrence of ORN (0.49 ± 0.11 /mm) 
(p=0.009). Otherwise, no significant differences were found between 
Groups 1 and 2. 
 
DISCUSSION 
In patients exposed to radiation therapy, radiation-induced skin 
irritations can cause undesired complications, such as soft tissue 
ulcers with reduced wound healing ability and prolonged healing 
progress. Additional alveolar bone trauma and surgery such as tooth 
extraction after irradiation to impaired soft tissue healing state are 
considered major initiating risk factors for ORN (6). Early treatment 
of radiation-induced tissue can lessen pain and reduce secondary 
infection and damage of adjacent tissues. Impaired wound healing in 
the oral mucosa and alveolar bone due to blood vessel damage after 
irradiation could be improved by exogenous or endogenous angiogenic 
factors (25). Recently, stem cell therapy has been proposed as a 
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complementary therapy to conventional surgical treatment for 
radiation-induced ulceration (12, 38, 44, 45). Bone marrow-derived 
MSCs can differentiate into myofibroblasts or epithelium can become 
blood vessel cells and perifollicular cells, which later form hair follicles 
during the wound healing process and play an important role in the 
formation of healthy tissues (46-48). Exogenous MSCs can produce 
growth factors for angiogenesis, such as VEGF and FGF (49, 50). 
Therefore, they can stimulate wound healing of hard and soft tissue 
lesions arising from local ischemia like ORN.  
Although the precise mechanism by which bone marrow-derived 
mesenchymal stem cells aid wound healing is not yet clear, enhanced 
healing effects have been reported (51, 52). Several studies in 
irradiated animal models have reported therapeutic effects of 
allogenous or autologous human MSCs and rMSCs using a variety of 
application methods and times (12, 53-56). In the study by Huang et 
al., adipose-derived stem cells enhanced healing in irradiated skin 
lesions. Cells were injected three, four, and five weeks after 
irradiation and animals were sacrificed at three weeks after the first 
injection for soft tissue analysis. Part I of this study also demonstrated 
therapeutic effects on soft tissue immediately after injection; however, 
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extension of analysis to five weeks postinjection revealed no 
significant results. Histological examination showed that the 
epithelium tended to be less eroded in the rMSC treatment group 
compared with the control group. However, no significant differences 
were observed between the two groups. The different results 
regarding the effects of rMSCs may be due to factors such as the 
amount of radiation absorbed, the nature of the irradiation site, and the 
amount/origin of the MSCs. 
In an analysis of the human and murine MSC transcriptomes, 
Tremain and colleagues found that MSCs express transcripts encoding 
proteins that regulate a broad range of biological activities, including 
angiogenesis and wound repair (22). Recent studies have suggested 
that the trophic capacity of MSCs to alter the tissue microenvironment 
may play a more prominent role than their transdifferentiation to 
achieve tissue repair (16, 23, 57, 58). This alteration to a more 
favorable tissue microenvironment may have led to the significantly 
increased bone volume in Group 2 of part II of the present study, 
where rMSCs were applied after the onset of ORN. In comparison, 
application of rMSCs immediately after bony defect formation was not 
as effective. Before the onset of ORN, the need for alteration in tissue 
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microenvironment would have been minimal.  
Several efforts have been made to enhance the therapeutic effect of 
stem cells in the treatment of chronic wounds by administering them 
in combination with various growth factors (59, 60). PDGF has been 
reported to contribute to wound healing through its proangiogenic 
effects (61, 62). Moreover, PDGF is a major regulator of the growth, 
proliferation, survival, and chemotaxis of MSCs (63-65). Previous 
studies have reported that PDGF exerts therapeutic effects on wound 
healing (66-71). In this study, no significant difference was observed 
between the experimental and control sides when PDGF-BB was 
injected at the irradiated area (part I). Although similar doses of PDGF 
were used in the previous studies and in our study, the relative amount 
of PDGF was different in this study, since the previous studies used 
daily topical application while we performed subcutaneous injection. 
Also, the previous studies examined surgically formed wounds, while 
this study examined radiation-induced wounds. Improvement of 
wound healing by application of PDGF to radiation-damaged tissue 
was not observed in this study. Radiation exerts a negative effect on 
the mitogenic potential of PDGF (72); thus, the normal function of 
PDGF could have been impaired in irradiated skin.  
Based on studies of interactions between MSCs and PDGF on the 
39 
 
cellular level (60, 73, 74), we investigated the clinical effect of 
applying MSCs in combination with PDGF. Yan et al. reported that 
human platelet-derived growth factor A-modified cultured cutaneous 
substitute cells (porcine bone marrow-derived mesenchymal stem 
cells and keratinocytes) promoted the healing of radiation-induced 
skin ulceration (73). After differentiation, MSCs primarily express 
PDGF receptor beta, which along with its ligand PDGF-β plays a key 
role in mediating tropism and differentiation during vascular 
remodeling (74). PDGF directly affecting differentiation and tropism 
of rMSCs during angiogenesis (75-78), a major process during skin 
regeneration, may have contributed to the significant therapeutic 
results seen in group c of this study where rMSCs and PDGF were 
applied in combination.   
BMP-2, another prominent growth factor, has an angiogenic effect, 
in addition to stimulating osteogenesis (79). Implantation of 
recombinant human BMP-2/poly-lactide-co-glycolic acid in necrotic 
rabbit femoral heads helped recover from necrosis and increased the 
local blood supply to normal levels, with bone formation in the 
defective area after medullary cavity decompression (80). In addition, 
a gelatin sponge containing BMP-2 had angiogenic and osteogenic 
effects when it was applied to bony defects in the rabbit radius (81). 
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In the present study (part II), application of a hydrogel containing 
BMP-2 led to increased bone formation immediately after bony defect 
formation and after the onset of ORN. These results suggest that 
application of BMP-2 could be useful in treatment of ORN, where 
vessel formation capacity is decreased.  
The healing effect of BMP-2 or rMSCs can differ depending on the 
time of application. Because the experimental conditions differ 
between groups 1 and 2, there is a limit in directly comparing the two 
groups. Within each group, differences in healing could be seen 
according to treatment modality.  In this study (part II), the 
application of BMP-2 alone resulted in higher bone volume and bone 
mineral density than application of rMSCs alone when the hydrogel 
transplantation was done immediately after surgical trauma (Group 1). 
When the hydrogel transplantation was performed after ORN had 
occurred (Group 2), rMSC-applied specimens and BMP-2-applied 
specimens showed similarly enhanced bone volume; between the two, 
rMSC application brought about higher increase in BMD and Tb.Th. 
When BMP-2 and rMSCs were applied in combination, the most bone 
healing effect was seen by significant increases in BV, BMD, and Tb.N. 
The effect of rMSCs may have been more pronounced after the 
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occurrence of ORN due to the status of the recipient alveolar bone. 
Although animals in Group 2 received local debridement of the 
contaminated and necrotic recipient site, more contaminated residual 
necrotic alveolar bone and a lack of soft tissue coverage were also 
present in that group, where rMSCs could have played a role in the 
changing tissue microenvironment.  
The 30-Gy single dose of radiation used in part II of the present 
study is higher than doses used in previous animal ORN models (82-
86); however, bone necrosis did not occur in previous experiments. 
In 2011, Cohen et al. created a rat model of advanced ORN using high 
dose rate (30 Gy) brachytherapy (83) after molar extraction without 
an alveolar bone defect, where the mortality rate was 16% (1/6 rats). 
The mortality rate in the present study was much higher (43.0%). The 
main factors for this high mortality were complications during 
preparation of the surgical bone defect. These included severe 
bleeding from the inferior alveolar artery and vein after the removal 
of mandibular bone (14.0%) and anesthetic overdose (13.2%) to 
reduce pain after damage to inferior alveolar nerve, which is somewhat 
unavoidable when creating consistent bone defects. In order to 
objectively compare the osseous healing effects of BMP-2 and/or 
rMSCs among different groups, the initial osseous condition were kept 
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as constant as possible for each rat.  
Hyaluronic acid based hydrogel is an excellent carrier for new bone 
formation. The bone forming effect of BMP-2 and/or human 
mesenchymal stem cell carried with hyaluronic acid hydrogel on rat 
calvarial defects was previously reported (41). Bae MS et al. reported 
the generation and effect of hyaluronic acid (HA) hydrogels loaded 
with growth and differentiation factor five on in vitro and in vivo 
osteogenesis (87). In particular, HA-based hydrogels synthesized 
using matrix metalloproteinase (MMP) sensitive acrylated HA 
mimicked the remodeling characteristics of natural extracellular 
matrices by cell-derived MMPs. These hydrogels have been reported 
to improve tissue remodeling rates and bone regeneration activity 
when used as scaffolds for BMP-2 and MSCs (40). In the present 
study, hydrogel was an effective carrier of BMP-2 and MSCs, as BV 
and BMD were increased or well-recovered in Groups 1d, 2c, 2d, and 
2e.  
This study demonstrated the therapeutic effects of growth factor and 
MSC application on necrotic soft and hard tissue following irradiation 
in rats. Further studies on middle and large sized animals are needed 
to investigate the application of MSCs and growth factors as treatment 
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In conclusion, neither rMSCs alone nor PDGF alone exerted any 
significant therapeutic effect in a rat model of radiation-induced soft 
tissue injury. However, when rMSCs were administered in 
combination with PDGF onto rat skin that already had radiation-
induced soft tissue injury, the early stage of wound healing was 
significantly enhanced. Ulcer size also tended to be smaller when the 
rMSC/PDGF treatment was applied immediately after irradiation. 
These results will contribute to future efforts to successfully prevent 
and treat soft tissue ulceration that occurs as a complication of 
radiation therapy.  
The present study also suggests that MSCs and/or BMP-2 carried 
with a hyaluronic acid-based hydrogel can be effective for bone 
regeneration in ORN. This effect may be enhanced immediately after 
dentoalveolar trauma or surgery by application of BMP-2. After the 
occurrence of ORN, the combined application of rMSCs and BMP-2 
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Table 2. Ulceration in percentage 
Ulceration in 
percentage (%) 
(Mean ± SD) 
Days after administration 
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Table 3. Classification of groups. 















0 week 0 weeks Defect formation only 
 1a 
radiation 1 week 1 week 
Defect formation only 
 1b 
Hydrogel application immediate after defect 
formation  
 1c 
Hydrogel + rMSCs application immediate after 
defect formation  
 1d 
Hydrogel + BMP-2 application immediate after 
defect formation  
 1e 
Hydrogel + rMSCs + BMP-2 application 
immediate after defect formation  
2a 
radiation 1 week 5 weeks 
Curettage only 
2b Hydrogel application immediate after curettage 
2c 
Hydrogel + rMSCs application immediate after 
curettage 
2d 
Hydrogel + BMP-2 application immediate after 
curettage 
2e 
Hydrogel + rMSCs + BMP-2 application 









Table 4. Data (average ± SD) of BV and BMD in each group.  
 BV (㎣) BMD (%) 
 Negative control(no radiation) 4.78 ± 1.53 1.50 ± 0.07 
 Group 1 
 Positive control 2.26 ± 1.94 1.34 ± 0.10 
 Hydrogel 4.27 ± 0.45 1.40 ± 0.05 
 Hydrogel + rMSCs 4.51 ± 0.45 1.48 ± 0.05 
 Hydrogel + BMP-2 6.29 ± 1.63 1.58 ± 0.08 
 Hydrogel + rMSCs + BMP-2 4.87 ± 1.29 1.44 ± 0.08 
Group 2 
Positive control 1.98 ± 0.71 1.32 ± 0.07 
Hydrogel 1.32 ± 0.79 1.26 ± 0.03 
Hydrogel + rMSCs 5.41 ± 1.77 1.48 ± 0.12 
Hydrogel + BMP-2 5.71 ± 0.94 1.44 ± 0.05 










Table 5. Soft tissue coverage at the end of experiment.   
Group 










  6 6 
1a 1 4  5 
1b 2 3  5 
1c  1 4 5 
1d  1 4 5 
1e  2 3 5 
2a 2 3  5 
2b 2 3  5 
2c  2 3 5 
2d  1 4 5 









Figure 1. Analysis of ulcer size. (a) Image of a representative 




Figure 2. Flow cytometry. Flow cytometric analysis showing the 







Figure 3. Modified skin scores. Changes in the modified skin scores 
after injection of (a) rMSCs (Group A), (b) PDGF (Group B), and (c) 























































Figure 4. Skin ulceration ratio. Changes of the skin ulceration ratios 
(%) in (a) Group A (rMSCs), (b) Group B (PDGF), and (c) Group C 
(rMSCs + PDGF). Asterisks indicate statistically significant 




































































Figure 5. Photography of skin wound. Wound healing progress in 
Group A (rMSCs), B (PGDF), and C (rMSCs + PDGF) at different 
















Figure 6. Histology. Histological images of radiation-induced skin 
wounds at 35 days postinjection. (a) HE staining of a representative 
skin wound from Group A (MSC treatment). Less edema (asterisk) 
was observed compared with the vehicle control (b). (c) 
Representative skin wound from Group B (PDGF treatment). More 
highly organized collagen fiber deposition (asterisk) was observed 
throughout the entire dermis layer compared with the vehicle control 
(d). (e) HE staining of a representative skin wound from Group C 
(rMSCs + PDGF). The wound was re-epithelialized with regenerated 
skin appendages (arrow). (f) HE staining of a representative skin 
wound from the control side in Group C. Reduced re-epithelialization 









Figure 7. rMSCs tracking. Tracking of injected rMSCs at three (a) and 
seven (b) days after injection. Cultured rMSCs were labeled with 
fluorescent dialkylcarbocyanine (Dil) dye (10 ng/mL) and 
subcutaneously injected into the radiation-induced ulcer area at three 
weeks postirradiation. Proliferating cell nuclear antigen (PCNA) 
(green) was used to confirm the viability of the rMSCs. rMSCs 
















Figure 8. Surgery. (a) All three molars on the right side of the rat 
mandible were extracted, and afterwards the bony defect was formed. 
(b) In group 1, hydrogel was applied immediately. (c, d) In group 2, 
ORN was verified four weeks after formation of the bony defect, and 
a flap was elevated to perform curettage of contaminated denuded 
bone, after which the hydrogel was applied. 
 
 




Figure 9. Definition of ROI. ROI was defined as a volume of width 50 













Figure 10. Occurrence of osteoradionecrosis. 3D micro-CT image and 
histological image (HE staining) four weeks after extraction of molars 
in the negative control (no radiation) and positive control (radiation 
only). (a) 3D micro-CT image of mandible with normal extraction 
socket in the negative control; (b) 3D micro-CT image of a mandible 
with ORN at the extraction socket in the positive control; (c) 
histological image of a mandible with a normal extraction socket in the 
negative control; (d) histological image of a mandible with ORN at the 
extraction socket in the positive control; exposed alveolar bone 
without epithelial coverage, obliterated blood vessels and reduced 








Figure 11. BV and BMD in Groups 1 (a) and 2 (b). (a) BV and BMD 
were significantly greater in Group 1d than in Group 1a. The asterisk 
(*) indicates a p-value of <0.05 (p=0.001 and p=0.002, respectively) 
compared to the positive control (Group 1a). N.C. indicates the 
negative control. Gr.1a: positive control in group 1; Gr.1b: hydrogel 
only; Gr.1c: hydrogel containing rMSCs; Gr.1d: hydrogel containing 
BMP-2; Gr.1e: hydrogel containing rMSCs and BMP-2. (b) Groups 
2c, 2d and 2e had significantly greater BV than Group 2a. The asterisk 
(*) indicates a p-value of <0.05 (p=0.003, p=0.002 and p=0.015, 
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2d and 2e had significantly greater BV than Group 2b. The asterisk 
(**) indicates a p-value of <0.05 (p=0.000, p=0.000 and p=0.001, 
respectively) compared to hydrogel only (Group 2b). BMD in Group 
2e was significantly greater than Group 2a. The asterisk (*) indicates 
a p-value of <0.05 (p=0.01) BMD in Group 2c and 2e were 
significantly greater than Group 2b. The asterisk (**) indicates a p-
value of <0.05 (p=0.002 and p=0.000, respectively) compared to 
hydrogel only (Group 2b). N.C. indicates negative control. Gr.2a: 
positive control in group 2; Gr.2b: hydrogel only; Gr.2c: hydrogel 
containing rMSCs; Gr.2d: hydrogel containing BMP-2; Gr.2e: 








Figure 12. 3D reconstruction of micro CT images in Group 1. (a) Group 
1a. Bone resorption is observed.  (b) Group 1d. Following hydrogel 












Figure 13. (a) Group 2a. Bone resorption is observed. (b) Group 2e. 
Following hydrogel application containing both rMSCs and BMP-2, 









Figure 14. Histological evaluation of a mandibular defect model after a 
four-week application of hydrogel in Groups 1 and 2. (a) Incomplete 
regeneration of the epithelium with delayed bone healing in Groups 1a 
and 1b, but new bone formation with full coverage of the oral 
epithelium in Groups 1c, 1d, and 1e. (b) Incomplete regeneration of 
the epithelium with delayed bone healing was observed in Groups 2a 
and 2b, while new bone formation with full coverage of oral epithelium 


































Figure 15. Comparison of histological results between Groups 1 and 2. 
(a) Regenerated alveolar bone with slight inflammation, even with 
incomplete epithelial regeneration in Group 1b; (b) normal bone 
structure without inflammation under full coverage of oral epithelial 





addition to resorptive changes with inflammation in Group 2b; (d) 
regenerated alveolar bone with normal bone structure, but a small 




백서에서 방사선조사에 의한 피부궤양과 골괴사 치료를 위한 
골수유래 줄기세포와 PDGF/BMP-2의 적용 효과 
진 임 건 
서울대학교 대학원 치의과학과 구강악안면외과학 전공 
(지도교수 황 순 정) 
 
연구 목적 
악골의 방사선골괴사(ORN)는 악안면 영역의 방사선 치료 이후 발생하
는 주요 합병증 중 하나로 대증요법만으로 치유되는 경우도 있으나 경우
에 따라 악골의 변형 및 악골기능의 손상을 유발하기도 하며 이 경우 결
손부의 재건수술이 이루어지더라도 그 경과가 만족스럽지 못한 경우가 많
다. 방사선골괴사는 방사선 조사 후 연조직 혹은 점막의 손상으로 골조직
이 노출된 후 3~6개월간 치유되지 않고 지속되는 병변으로 정의된다. 방
사선골괴사의 초기 단계에서는 연조직의 괴사가 발생하고 골조직의 노출
이 일어나며 방사선골괴사가 진행됨에 따라 노출된 피질골 뿐만 아니라 
하방의 망상골 또한 괴사되고 결국 괴사는 하악골의 하연까지 진행된다. 
방사선골괴사의 기전은 명확하게 정립되어 있지 않아 방사선골괴사에 대
한 직접적인 치료법은 확립되지 못했다. 방사선골괴사는 연조직의 괴사에
서 시작되기 때문에 연조직 병변 단계에서 조직의 치유를 촉진하거나 괴
사의 진행을 늦출 수 있다면 이어지는 골조직의 노출을 최소화할 수 있다. 
골조직의 노출 이후에는 골괴사 단계에서 골조직의 치유를 촉진할 수 있
다면 방사선골괴사의 치료를 기대할 수 있다. 최근, 골수유래줄기세포의 
상처치유에 대한 다양한 효과들이 보고된 바 있다. 그러나 방사선골괴사
의 진행 단계에 있어서 골수유래줄기세포 단독으로 혹은 성장인자와 함께 
적용하여 그 치유 효과에 대한 연구는 부족한 편이다. 이에 본 연구에서
는 골수유래줄기세포 단독 혹은 혈소판유래 성장인자(platelet derived 
growth factor, PDGF)와 함께 적용하여 골수유래줄기세포 혹은 혈소판유
래 성장인자가 백서에서의 방사선 유발 연조직 병변의 치유에 미치는 영
향을 규명하고 백서 하악골의 방사선골괴사 모델에 골수유래줄기세포 단
독 혹은 골형성단백질-2와 함께 적용하여 적용시기에 따른 골조직의 치
유에 미치는 효과를 규명하고자 하였다. 
Part I. 방사선 유발 연조직 손상부에 대한 효과 
[재료 및 방법]  
17마리의 백서(Sprague-Dawley) 좌우 둔부에 50 Gy의 방사선을 조
사하였다. 방사선 조사 후 3주후 우측 둔부에는 대조군으로 인산염 완충 
용액을 적용하였고, 좌측 둔부는 골수유래줄기세포(rMSCs)(2 x 106 cells)
단독 적용, 혈소판유래 성장인자 (8 µg) 단독 적용 혹은 골수유래줄기세
포 및 혈소판유래 성장인자 혼합 적용을 시행하였다. 상처치유는 적용 후 
5주간의 치유 기간 동안 전체 방사선 조사부 대비 잔존 궤양 면적 비율
을 측정하여 분석하였고, 치유기간 동안 정량적 평가법(Modified skin 
scores)을 시행하여 골수유래줄기세포 및 성장인자 적용 후 치유 정도를 
평가하였다. 이후 연조직 병변은 조직염색으로 평가하였다. 
[연구 결과] 
방사선 조사 후 16일 이내에 방사선 조사부위의 40% 이상에서 궤양이 
발생하였으며 3 주 경과 후 궤양은 방사선 조사면적의 50%가 넘는 최대 
크기에 도달 하였다.  골수유래줄기세포 단독 적용군과 혈소판유래 성장
인자 단독 적용군에서는 유의할 치유 효과가 관찰되지 않았다. 골수유래
줄기세포 및 혈소판유래 성장인자 혼합 적용군에서는 적용 후 2주간 궤
양 면적 비율에 있어서 대조군 대비 유의한 감소가 관찰되었다. 조직염색 
결과 혈소판유래 성장인자 단독 적용군 및 골수유래줄기세포 및 혈소판유
래 성장인자 혼합 적용군에서 대조군 대비 고형질의 교원섬유가 진피층 
전부위에서 관찰되었다.   
 
Part II. 방사선유발 골괴사에 대한 효과 
[재료 및 방법]  
비폐쇄형 피부클램프를 사용하여 백서의 체부와 내장을 보호하고 
image guided stereotactic irradiator를 사용하여 하악골에 방사선 조사
를 시행하였다. 조사거리는 100 cm로 일정하였으며 30Gy의 방사선을 백
서의 우측 하악 동일부에 조사하였다. 방사선 조사 일주일 후 우측 하악
골의 모든 구치에 대해 발거술 및 동일한 크기의 외상부 형성을 시행하였
다. 백서는 하이드로젤 복합체의 적용시기에 따라 두 군으로 임의로 분류
되었다(각 그룹당 n=25).  1군에서는 외상형성 직후 외상부에 골수유래
줄기세포 혹은 골형성단백질-2를 포함한 하이드로젤을 적용하고 4주간 
경과관찰 하였다. 2군에서는 외상부 형성 후 4주 경과 후 방사선골괴사의 
발생을 확인 한 후 골수유래줄기세포 혹은 골형성단백질-2를 포함한 하
이드로젤을 적용하고 4주간 경과관찰 하였다. 각 실험군은 대조군 (n=5), 
하이드로젤 단독 적용군(n=5), 골수유래줄기세포 2 x 104 를 포함한 하
이드로젤 적용군 (n=5), 10 ㎍의 골형성단백질-2를 포함한 하이드로젤 
적용군 (n=5), 골수유래줄기세포 2 x 104 및 10 ㎍의 골형성단백질-2 
혼합하여 포함된 하이드로젤 적용군(n=5)로 구성되었다. 골조직 치유를 
평가하기 위하여 미세초첨 컴퓨터단층촬영을 시행하여 각 그룹간 비교를 
하였다. 방사선 조사를 받지 않고 외상부 형성만 시행받은 백서에 대해서 
음성대조군으로 비교 분석 하였다.   
[연구 결과] 
1 군에서는 골형성단백질-2가 포함된 하이드로젤 적용군에서 골부피
(bone volume, BV) 및 골밀도(bone mineral density, BMD)의 유의한 
증가가 관찰되었으나 골수유래줄기세포를 적용하는 경우 대조군 대비 평
가 항목에서 유의한 차이가 관찰되지 않았다. 2 군의 모든 개체에서 방사
선골괴사가 발생한 것이 관찰되었다. 2군에서는 골수유래줄기세포 및 골
형성단백질-2가 혼합 포함된 하이드로젤 적용시 하이드로젤 단독 적용군 
및 대조군 대비 골부피 및 골밀도의 유의한 증가가 관찰되었다. 1군에서 
골형성단백질-2가 포함된 하이드로젤을 적용한 군(6.29 ± 1.63%) 은 
2군에서 골형성단백질-2가 포함된 하이드로젤을 적용한 군(5.71 ± 
0.94%)에 비해 골밀도가 유의미하게 높은 것으로 관찰되었다.   
결론 
백서의 방사선유발 연조직 궤양에서 골수유래 줄기세포와 혈소판유래 성
장인자 혼합 적용시 유의한 치유증대 효과가 관찰되었다. 백서에서 방사
선 조사 후 형성한 외상부 골조직의 치유는 치조골외상부 형성 직후 골형
성단백질-2를 포함한 하이드로젤 적용시 치유 증대가 관찰되었다. 반면 
방사선골괴사 발생 이후 적용시에는 골수유래줄기세포 및 골형성단백질-
2의 혼합 포함된 하이드로젤 적용시 골조직의 치유 증대 효과가 관찰되
었다. 
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